WuXi AppTec’s sales are becoming even more increasingly dependent on the US despite the service provider not yet fully shaking off concerns over its ties
Parkinson’s stem cell therapy developer Oryon Cell Therapies started out Monday morning with three announcements: It enlisted Ron Cohen as its new CEO, netted an
Biotech takeover specialist Kevin Tang is consolidating control at Aurinia Pharmaceuticals, and has replaced the CEO and C-suite at the company, according to a securities
Plus, news about Opdivo: 📊 Dizal drug succeeds in Phase 3 lung cancer study: The drug Zegfrovy improved progression-free survival compared to chemo in first-line
Sanofi has licensed rights to Kali’s trispecific T-cell engager KT501, in trials for rheumatoid arthritis, in a deal valued at nearly $1.2bn.
Insmed’s Phase 3 trial win for Arikayce in a particular kind of lung infection sets up the drug to expand into the front-line setting — possibly giving the biotech a second projected blockbuster.
The company said …
Copyright 2025 dijee Intelligence Ltd. dijee Intelligence Ltd. is a private limited company registered in England and Wales at Media House, Sopers Road, Cuffley, Hertfordshire, EN6 4RY, UK registration number 16808844